Lupin Receives Approval From USFDA For Febuxostat Tablets

Lupin Receives Approval From USFDA For Febuxostat Tablets

The product will be manufactured at Lupin’s Pithampur facility in India.

FPJ Web DeskUpdated: Thursday, January 18, 2024, 05:31 PM IST
article-image
Lupin Receives Approval From USFDA For Febuxostat Tablets | Image: Wikipedia (Representative)

Global pharma major Lupin Limited (Lupin) on Thursday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Febuxostat Tablets, 40 mg and 80 mg, to market a generic equivalent of Uloric Tablets, 40 mg and 80 mg, of Takeda Pharmaceuticals U.S.A., Inc., the company announced through an exchange filing.

The product will be manufactured at Lupin’s Pithampur facility in India.

Febuxostat Tablets, 40 mg and 80 mg, are indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.

Febuxostat Tablets (RLD Uloric) had estimated annual sales of USD 27 million in the U.S. (IQVIA MAT November 2023).

Lupin Limited shares

The shares of Lupin Limited on Thursday at 3:30pm IST were at Rs 1,425.45, up by 1.83 per cent.

RECENT STORIES

On Market's Mind: US Fed, Israel-Iran Conflict And Q4 Earnings Will Decide Performance Next Week

On Market's Mind: US Fed, Israel-Iran Conflict And Q4 Earnings Will Decide Performance Next Week

'30 Crore Consumers In 4 Months': Free Safety Check For All LPG Connections By Govt Oil Companies

'30 Crore Consumers In 4 Months': Free Safety Check For All LPG Connections By Govt Oil Companies

₹20,000 In 4 Days: FIIs Shed In Volumes Amid Election And Global Uncertainties

₹20,000 In 4 Days: FIIs Shed In Volumes Amid Election And Global Uncertainties

Direct Tax Collections Exceed Estimates In FY24; Jump 18% To ₹19.58 Lakh Crore

Direct Tax Collections Exceed Estimates In FY24; Jump 18% To ₹19.58 Lakh Crore

Smooth, Sleek And Sedan: 2024 Audi A3

Smooth, Sleek And Sedan: 2024 Audi A3